APPROVAL FRAMEWORKS FOR REGENERATIVE MEDICINE IN JAPAN: STATUTORY GOVERNANCE, CLINICAL AUTHORISATION AND JUDICIAL ACCOUNTABILITY

1. INTRODUCTION

Regenerative medicine involves the use of living cells, tissues, stem cells and gene-based technologies to repair, replace or regenerate damaged biological structures and restore physiological functions. Its applications include stem-cell transplantation, induced pluripotent stem-cell (iPSC) therapy, tissue engineering, cellular immunotherapy and gene therapy.

Japan has developed a distinctive regulatory framework to encourage regenerative medicine innovation while maintaining patient safety, scientific accountability and clinical oversight. Its principal legislation consists of the Act on the Safety of Regenerative Medicine (ASRM) and the Pharmaceuticals and Medical Devices Act (PMD Act).

The regulatory system distinguishes between regenerative medicine provided as medical practice or research and regenerative medical products developed for commercial marketing. This distinction determines the applicable approval procedures, institutional responsibilities and regulatory authorities.

2. PRINCIPAL LEGISLATIVE FRAMEWORK

A. ACT ON THE SAFETY OF REGENERATIVE MEDICINE, 2014

The ASRM establishes safety requirements for regenerative medicine research and clinical practice involving qualifying cellular and related technologies.

Its principal objectives include:

Protection of patients receiving regenerative interventions.

Institutional review of regenerative medicine plans.

Risk-based classification of regenerative medicine.

Supervision of cell-processing facilities.

Monitoring of adverse events.

Regulatory intervention against unsafe clinical practices.

B. PHARMACEUTICALS AND MEDICAL DEVICES ACT

The PMD Act regulates regenerative medical products intended for commercial development and distribution.

It covers qualifying processed human or animal cellular products and specified gene therapy products.

The legislation establishes marketing authorisation, quality assurance, clinical evaluation, manufacturing supervision and post-marketing safety obligations.

C. REGENERATIVE MEDICINE PROMOTION ACT, 2013

This legislation provides a national policy framework for promoting regenerative medicine research, development and public access while supporting appropriate safety measures.

D. CLINICAL TRIALS ACT, 2017

The legislation establishes requirements for specified clinical research, including ethical review, informed consent, research transparency and institutional accountability.

The PMDA confirms that the ASRM and PMD Act became effective in November 2014 and operate as complementary regulatory frameworks. <Cite refs={["turn564628search0","turn564628search2"]}/>

3. REGULATORY AUTHORITIES

The principal regulatory institutions include:

MHLW: Establishes regulatory policy and administers the applicable statutory framework.

PMDA: Conducts scientific review, regulatory consultations, inspections and safety assessments.

Certified Regenerative Medicine Committees: Review relevant regenerative medicine plans.

Institutional Review Boards: Examine applicable research ethics and patient protection.

Healthcare Institutions: Maintain clinical governance, treatment records and patient-safety procedures.

4. CLASSIFICATION AND AUTHORISATION FRAMEWORK

The ASRM establishes a risk-based classification system.

A. CLASS I REGENERATIVE MEDICINE

Includes technologies considered to involve higher potential risks, such as certain interventions involving pluripotent stem cells and genetically modified cells.

B. CLASS II REGENERATIVE MEDICINE

Includes qualifying interventions involving cultured somatic cells and other cellular technologies presenting intermediate risks.

C. CLASS III REGENERATIVE MEDICINE

Includes qualifying lower-risk regenerative interventions, such as specified minimally manipulated cellular treatments.

The classification determines the applicable committee review, notification and regulatory procedures. Class I and II generally require review by a Certified Special Committee for Regenerative Medicine, while Class III is generally reviewed by a Certified Committee for Regenerative Medicine.

5. COMMERCIAL APPROVAL PROCEDURE

Regenerative medical products seeking commercial marketing authorisation follow the PMD Act pathway.

A. PRECLINICAL EVALUATION

The sponsor establishes appropriate evidence concerning product quality, biological characteristics, safety and relevant non-clinical performance.

B. CLINICAL DEVELOPMENT

Clinical trials must comply with applicable GCP requirements, including scientific validity, ethical review and informed consent.

C. PMDA REVIEW

The PMDA evaluates manufacturing quality, clinical safety, efficacy and the overall benefit-risk profile.

D. MHLW MARKETING AUTHORISATION

The marketing application proceeds through the statutory Japanese approval system following scientific assessment.

E. POST-MARKETING SUPERVISION

Approved products remain subject to safety reporting, use-results surveys, applicable re-examination and regulatory inspections.

6. CONDITIONAL AND TIME-LIMITED APPROVAL

Article 23-26 of the PMD Act provides conditional and time-limited approval for eligible regenerative medical products.

This mechanism allows earlier commercial access where safety has been established and efficacy can reasonably be predicted from the available clinical evidence, subject to statutory conditions.

Important requirements include:

Adequate preliminary safety evidence.

A reasonable prediction of clinical efficacy.

Defined approval conditions.

A subsequent efficacy evaluation plan.

Collection of additional clinical evidence.

Regulatory reassessment within the approval period.

The conditional approval period cannot exceed seven years. It is not equivalent to unrestricted permanent approval.

Japan's framework was further clarified through MHLW guidance issued in March 2024 and October 2025. <Cite refs={["turn564628search12","turn564628search13"]}/>

7. IMPORTANT JUDICIAL DECISIONS AND LEGAL PRECEDENTS

Japan has limited reported judicial precedent specifically addressing regenerative medicine approval. The following decisions and proceedings provide relevant legal principles.

1. Jehovah's Witness Blood Transfusion Case, Supreme Court of Japan (29 February 2000) — DIRECT MEDICAL-CONSENT AUTHORITY

The Supreme Court recognised liability where physicians failed to explain their hospital's transfusion policy to a patient who had firmly refused blood transfusion. The decision supports informed consent and patient autonomy in regenerative treatment.

2. Breast-Conserving Surgery Case, Supreme Court of Japan (2000) — ANALOGOUS AUTHORITY

The Court addressed physicians' duties to explain relevant alternative treatments. Its reasoning is relevant when patients are considering experimental regenerative interventions alongside established treatments.

3. Japanese Stem Cell Clinic Civil Liability Case (reported in 2015) — DIRECT REGENERATIVE-MEDICINE AUTHORITY

A Japanese civil court awarded compensation against a private stem-cell clinic after finding that the patient had not been adequately informed of risks associated with mesenchymal stem-cell infusion, particularly in view of pre-existing medical conditions. The reported award included treatment costs and an additional ¥500,000 in damages. The published secondary account does not identify the court, date or case number, so these particulars should not be treated as verified.

4. Japanese Cancer Diagnosis Disclosure Litigation — ANALOGOUS AUTHORITY

Japanese medical jurisprudence concerning disclosure of cancer diagnoses provides relevant principles regarding physicians' obligations to communicate material medical information and protect patient interests.

5. Japanese Medical Malpractice Jurisprudence — ANALOGOUS AUTHORITY

Judicial decisions applying professional negligence principles establish that medical practitioners must exercise appropriate professional care. These principles are relevant to unsafe regenerative interventions and inadequate patient monitoring.

6. Japanese Product Liability Jurisprudence — ANALOGOUS AUTHORITY

The Product Liability Act, 1994 provides a statutory basis for claims involving defective products. Its principles are relevant where defective cellular products or regenerative medical products cause legally compensable harm.

The first three authorities illustrate the importance of informed consent and the particular risks of unproven cellular treatments. The remaining authorities concern broader legal principles rather than regenerative medicine approval itself. <Cite refs={["turn436577view0","turn564628search0"]}/>

8. MANUFACTURING AND QUALITY-CONTROL OBLIGATIONS

Regenerative medicine manufacturers must maintain appropriate Good Gene, Cellular and Tissue-based Products Manufacturing Practice (GCTP) systems.

Compliance includes:

Cellular product identity and traceability.

Manufacturing consistency.

Contamination prevention.

Quality-control documentation.

Appropriate storage and transportation.

Batch release procedures.

Manufacturing facility inspections.

Corrective and preventive actions.

These requirements are particularly important for autologous and allogeneic cellular products.

9. RECENT DEVELOPMENTS AND REGULATORY CHALLENGES

Japan's regenerative medicine framework continues to evolve. On 6 March 2026, MHLW granted conditional and time-limited marketing approvals to two iPSC-derived products, RiHEART and AMCHEPRY, representing an important development in commercial iPSC-based medicine.

The principal continuing challenges include long-term safety assessment, tumour-related risks, manufacturing consistency, uncertain clinical effectiveness, equitable access and the quality of post-approval evidence. <Cite refs={["turn564628search3","turn564628search15"]}/>

10. PRACTICAL COMPLIANCE REQUIREMENTS

Research institutions, manufacturers and healthcare providers should:

Determine the correct statutory classification.

Obtain applicable committee review and regulatory authorisation.

Maintain scientifically justified treatment plans.

Establish informed-consent procedures.

Comply with GCTP and GCP requirements where applicable.

Maintain traceability and manufacturing documentation.

Report relevant adverse events.

Protect patient information.

Conduct post-treatment safety monitoring.

Maintain appropriate insurance and institutional accountability.

11. CONCLUSION

Japan's regenerative medicine approval framework combines the ASRM and PMD Act to regulate clinical practice, research and commercial development. Its risk-based classification system, PMDA scientific review, manufacturing standards and conditional approval pathway provide a structured approach to emerging cellular and gene-based therapies.

Judicial principles concerning informed consent, medical negligence, product defects and patient autonomy supplement statutory regulation by establishing accountability for unsafe treatment practices.

Ultimately, regenerative medicine must develop within a framework that protects patients, maintains scientific integrity, ensures manufacturing quality and makes clinical innovation subject to enforceable legal oversight.